#United States #NYSCF #Stem Cell Research #Jackson Laboratory #Bar Harbor

A Game-Changing Partnership in Biomedical Science

In a groundbreaking announcement made on July 9, 2025, The Jackson Laboratory (JAX) and The New York Stem Cell Foundation (NYSCF) have unveiled a new alliance aimed at redefining the landscape of biomedical research. This forward-thinking partnership is designed to harness their combined expertise in genomics, stem cell science, and AI-driven data analytics to expedite the discovery of transformative therapies for diseases affecting millions globally.

Joining Forces for Human Health

The shared mission to enhance human health has brought these two pioneering organizations together, setting the stage for significant advancements in disease research. JAX is internationally celebrated for its contributions to genomics and disease modeling, while NYSCF is at the forefront of stem cell technology and automation. By integrating their strengths, this collaboration seeks to create a robust platform that fosters unprecedented breakthroughs in human health.

Dr. Lon Cardon, president, and CEO of JAX, emphasized the transformational nature of this moment: "Through the integration of our complementary strengths, we are building a next-generation discovery engine that promises to overcome existing barriers in drug development, expediting therapies to patients in need."

Innovative Technology at the Core

Key to the success of this alliance will be the NYSCF Global Stem Cell Array®, an advanced robotic platform that enables extensive and reproducible stem cell research. This technology allows for the automation of patient-specific stem cell creation, providing an unparalleled level of precision and scalability in disease understanding and treatment testing. When paired with JAX's rigorous quality standards, this alliance aims to unlock new avenues for understanding disease mechanisms and therapeutic responses in ways never previously possible.

Jennifer Raab, president, and CEO of NYSCF, expressed enthusiasm about the collaboration, highlighting the potential for scientific research expansion in New York City and the global impact that such partnerships can achieve. "By integrating our technologies and expertise, we are creating an extraordinary environment to accelerate cures and improve health worldwide," she said.

Focus on Major Diseases

The partnership aims to significantly advance initiatives in a variety of critical medical fields including Alzheimer's and Parkinson's diseases, cancer, diabetes, rare diseases, and ocular diseases. With this unified approach, millions of patients around the world may find renewed hope as the institutions leverage their resources and knowledge to tackle these pressing health issues.

As part of the agreement, JAX will take over NYSCF's operations and assets, pending approval by the New York Attorney General. This restructuring will consolidate efforts under JAX's management, with headquarters located in Bar Harbor, Maine, a site recognized for its almost century-long history of biomedical research excellence.

NYSCF’s cutting-edge research facility in Manhattan will continue to play a pivotal role in these initiatives, retaining its identity as the JAX-NYSCF Collaborative. This transition reinforces both institutions’ commitment to long-term scientific collaboration across their diverse campuses in Maine, Connecticut, California, Florida, and Japan.

Demonstrating Leadership in Research

The cooperative spirit evident in this partnership is a step toward a future where innovative science plays a crucial role in combating major health challenges. Each organization brings its own legacy of pioneering technologies that have transformed medical research. Collaboratively, they aim to achieve what neither could accomplish alone—creating a framework for discovery that is expansive and far-reaching.

The Jackson Laboratory, established in 1929, is recognized as a leader in biomedical research with a focus on precision genomic solutions for diseases. The New York Stem Cell Foundation, a respected independent nonprofit, aims to accelerate cures and improve patient treatments through pioneering stem cell research. With this new alliance, both organizations plan to elevate their impact on global health positively.

This collaborative effort not only showcases the strength of unified scientific endeavor but also promises to change the trajectory of biomedical research, transforming how we understand and treat diseases in the years to come.